CAP (College of American Pathologists). 2007. HER2 and you: Guidelines provided by CAP and ASCO. Northfield, IL: CAP.

Cartron, G., L. Dacheux, G. Salles, P. Solal-Celigny, P. Bardos, P. Colombat, and H. Watier. 2002. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor Fc RIIIa gene. Blood 99(3):754–758.

CDC (Centers for Disease Control and Prevention). 2009. Genomic translation: ACCE model process for evaluating genetic tests. (accessed September 10, 2009).

CFF (Cystic Fibrosis Foundation). 2009. Patient registry report. (accessed September 28, 2009).

CMS (Centers for Medicare & Medicaid Services). 2009a. Medicare claims processing manual. Chap. 16, laboratory services. (accessed September 17, 2009).

CMS. 2009b. Medicare coverage database. (accessed September 28, 2009).

CMS. 2009c. Proposed decision memo for pharmacogenomic testing for warfarin response (CAG-00400N). (accessed September 24, 2009).

Di Nicolantonio, F., M. Martini, F. Molinari, A. Sartore-Bianchi, S. Arena, P. Saletti, S. De Dosso, L. Mazzucchelli, M. Frattini, S. Siena, and A. Bardelli. 2008. Wild-type BRAC is required for response to panitumumab or cetuximab in metastatic colorectal cancer. Journal of Clinical Oncology 26(35):5705–5712.

EGAPP Working Group (Evaluation of Genomic Applications in Practice and Prevention Working Group). 2009a. Recommendations from the EGAPP Working Group: Can tumor gene expression profiling improve outcomes in patients with breast cancer? Genetics in Medicine 11(1):66–73.

EGAPP Working Group. 2009b. Recommendations from the EGAPP Working Group: Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? Genetics in Medicine 11(1):15–20.

FDA (Food and Drug Administration). 1997. Medical devices; classification/reclassification; restricted devices; analyte specific reagents—FDA. Final Rule. Federal Register 62(225):62243–62260.

FDA. 2005. Drug-diagnostic co-development concept paper. Silver Spring, MD: FDA.

FDA. 2007a. Commercially Distributed Analyte Specific Reagents (ASRs): Frequently asked questions. (accessed September 19, 2009).

FDA. 2007b. Draft guidance for industry, clinical laboratories, and FDA staff: In vitro diagnostic multivariate index assays. Rockville, MD: FDA.

FDA. 2009a. Intercenter agreement between the Center for Drug Evaluation and Research and the Center for Devices and Radiological Health. (accessed September 28, 2009).

FDA. 2009b. Medical devices: General and special controls. (accessed September 23, 2009).

FDA. 2009c. Medical devices: In vitro diagnostics. (accessed September 23, 2009).

The National Academies of Sciences, Engineering, and Medicine
500 Fifth St. N.W. | Washington, D.C. 20001

Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement